EUVIMEDEUVIMED entdecken
Multizentrische Studie

Nephrotoxicity of Vancomycin in Combination With Beta-Lactam Agents: Ceftolozane-Tazobactam vs Piperacillin-Tazobactam

Sara Alosaimy iD, Abdalhamid M Lagnf, Athena L V Hobbs, Musa Mubarez, Wesley D Kufel, Taylor Morrisette, Radhika S Polisetty, David Li, Michael P Veve, Sam P Simon, James Truong, Natalie Finch und 21 weitere

Clinical Infectious Diseases · 2023

DOI: 10.1093/cid/ciac670 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Sara Alosaimy und 32 weiteren Autor:innen. Beteiligte Einrichtung: Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University…. Hauptthemen laut MEDLINE: Acute Kidney Injury, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Merck.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Vancomycin (VAN)-associated acute kidney injury (AKI) is increased when VAN is combined with certain beta-lactams (BLs) such as piperacillin-tazobactam (TZP) but has not been evaluated with ceftolozane-tazobactam (C/T). Our aim was to investigate the AKI incidence of VAN in combination with C/T (VAN/C/T) compared with VAN in combination to TZP (VAN-TZP).

Methods

We conducted a multicenter, observational, comparative study across the United States. The primary analysis was a composite outcome of AKI and risk, injury, failure, loss, end stage renal disease; Acute Kidney Injury Network; or VAN-induced nephrotoxicity according to the consensus guidelines. Multivariable logistic regression analysis was conducted to adjust for confounding variables and stratified Kaplan–Meir analysis to assess the time to nephrotoxicity between the 2 groups.

Results

We included VAN/C/T (n = 90) and VAN-TZP (n = 284) at an enrollment ratio of 3:1. The primary outcome occurred in 12.2% vs 25.0% in the VAN-C/T and VAN-TZP groups, respectively (P = .011). After adjusting for confounding variables, VAN-TZP was associated with increased odds of AKI compared with VAN-C/T; with an adjusted odds ratio of 3.308 (95% confidence interval, 1.560–6.993). Results of the stratified Kaplan–Meir analysis with log-rank time-to-nephrotoxicity analysis indicate that time to AKI was significantly shorter among patients who received VAN-TZP (P = .004). Cox proportional hazards analysis demonstrated that TZP was consistent with the primary analysis (P = .001).

Conclusions

Collectively, our results suggest that the AKI is not likely to be related to tazobactam but rather to piperacillin, which is a component in VAN-TZP but not in VAN-C/T.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Kidney InjuryDrug-Related Side Effects and Adverse ReactionsHumansVancomycinAnti-Bacterial Agentsbeta-LactamsRetrospective StudiesPiperacillin, Tazobactam Drug CombinationTazobactamPiperacillinDrug Therapy, CombinationCephalosporins

Stichwörter der Autor:innen

ceftolozane-tazobactamnephrotoxicitypiperacillin-tazobactamvancomycin

Substanzen

VancomycinAnti-Bacterial Agentsbeta-LactamsPiperacillin, Tazobactam Drug CombinationTazobactamPiperacillinceftolozaneCephalosporinsceftolozane, tazobactam drug combination

Autor:innen und Institutionen

  • Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
  • Department of Pharmacy, Baptist Memorial Hospital-Memphis, Memphis, Tennessee, USA.
  • Department of Clinical Pharmacy and Translational Science, University of Tennessee Health Science Center College of Pharmacy, Memphis, Tennessee, USA.
  • Department of Pharmacy Practice, Binghamton University School of Pharmacy and Pharmaceutical Sciences, Binghamton, New York, USA.
  • Department of Pharmacy, State University of New York Upstate Medical University, Syracuse, New York, USA.
  • Department of Clinical Pharmacy and Outcomes Sciences, Medical University of South Carolina College of Pharmacy, Charleston, South Carolina, USA.

ORCID-Profile: Sara Alosaimy

Förderung

  • Merck

Zitieren

APA

Alosaimy, S., Lagnf, A. M., Hobbs, A. L. V., Mubarez, M., Kufel, W. D., Morrisette, T., Polisetty, R. S., Li, D., Veve, M. P., Simon, S. P., Truong, J., Finch, N., Venugopalan, V., Rico, M., Amaya, L., Yost, C., Cubillos, A., Chandler, E., Patch, M., …, & Rybak, M. J. (2023). Nephrotoxicity of Vancomycin in Combination With Beta-Lactam Agents: Ceftolozane-Tazobactam vs Piperacillin-Tazobactam. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciac670

Vancouver

Alosaimy S, Lagnf AM, Hobbs ALV, Mubarez M, Kufel WD, Morrisette T, et al. Nephrotoxicity of Vancomycin in Combination With Beta-Lactam Agents: Ceftolozane-Tazobactam vs Piperacillin-Tazobactam. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciac670

BibTeX
@article{Alosaimy2023,
  author = {Alosaimy, Sara and Lagnf, Abdalhamid M and Hobbs, Athena L V and Mubarez, Musa and Kufel, Wesley D and Morrisette, Taylor and Polisetty, Radhika S and Li, David and Veve, Michael P and Simon, Sam P and Truong, James and Finch, Natalie and Venugopalan, Veena and Rico, Matthew and Amaya, Lee and Yost, Christine and Cubillos, Ashley and Chandler, Elisabeth and Patch, Megan and Smith, Ian Murphy Kelsey and Biagi, Mark and Wrin, Justin and Moore, W Justin and Molina, Kyle C and Rebold, Nicholas and Holger, Dana and Kunz Coyne, Ashlan J and Jorgensen, Sarah C J and Witucki, Paige and Tran, Nikki N and Davis, Susan L and Sakoulas, George and Rybak, Michael J},
  title = {Nephrotoxicity of Vancomycin in Combination With Beta-Lactam Agents: Ceftolozane-Tazobactam vs Piperacillin-Tazobactam},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  doi = {10.1093/cid/ciac670}
}
Kostenlos starten →